Skip to Content

ICON trial update: Ipi+Nivo combination with chemotherapy does not improve survival

In this MEDtalk, primary investigator and Oncologist Jon Amund Kyte presents the latest results from the ICON trial. ICON is a randomized phase IIb trial evaluating the efficacy and safety of chemotherapy combined with ipilimumab (Ipi) and nivolumab (Nivo) in patients with metastatic hormone receptor-positive (HER2+) breast cancer. Adding Ipi/Nivo combination to chemotherapy does not seem to improve the survival outcome, and more than half of the patients had an immune-related event (irAE).

Jon Amund Kyte

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top